CSG Gears Up for November 11 Update With Defence Leading, Ammo+ Lagging

CSG will report results for the first nine months of 2026 before the market opens on November 11, with a conference call scheduled for 10:00 CET. Ahead of that release, J&T Banka has published forecasts that sketch a company growing at a healthy clip but increasingly reliant on its defence arm, while a separate product announcement this week served as a reminder that not every headline development translates into booked business.

Defence Carries the Load

The broker projects revenue of EUR 5.18 billion for the nine-month period, a gain of 15.6% year on year. The mix behind that figure matters as much as the total. Defense Systems is expected to post a 17.4% increase in sales, whereas Ammo+ is seen declining 5% versus the prior-year period — though the unit should show sequential improvement from the immediately preceding quarter.

Whether that sequential recovery actually materialises in the numbers will go a long way toward determining the quality of the growth on display. A robust defence business helps, provided the softer performance elsewhere does not weigh on profitability more than anticipated.

Margin Stability Under the Microscope

J&T Banka forecasts an EBIT margin of 24.3%, against 24.1% reported for the first half of 2026 — a signal of broadly steady earning power despite the diverging trajectories of the two segments. Adjusted EBIT is pencilled in at EUR 1.26 billion, up 14.8%, with net profit from continuing operations expected at EUR 0.89 billion.

Should investors sell immediately? Or is it worth buying CSG?

For gauging operating profitability against company guidance, the operating margin offers the cleaner comparison, and here the analysts see continuity: CSG is expected to reaffirm its existing outlook. That guidance calls for 2026 revenue of EUR 7.4–7.6 billion and an operating margin of 24–25%.

Order Book and Tax Questions Loom

Beyond the earnings line, J&T Banka flags risks around the order backlog and a possible Czech sector tax. A durable backlog would give investors a case for continued growth — but only if management's commentary backs up expectations. The analysts also want detail on the MDA Space entry, which alongside the tax question could colour how the outlook is read. The upbeat profit forecast thus comes with a condition attached: that order intake and potential extra burdens do not cloud the growth picture.

Meander Makes Its Debut — as a Prototype

On the product front, CSG's Excalibur Army and New Space Technologies, part of Krill Business Partners, unveiled a first prototype of the Meander amphibious vehicle at the Future Forces Forum in Prague, according to media reports dated October 28. Payload is slated to reach up to 13 tonnes. As of October 23, no order for the vehicle had been publicly confirmed, so the presentation concerns a prototype rather than a secured purchase.

The picture differs on the US Army side, where subsidiary MSM North America has been selected as a qualified contractor under a modernisation framework running five years, with a shared ceiling of $4.2 billion across the chosen contractors. The programme covers seven munitions facilities, with individual projects competed separately. Selection therefore guarantees neither a specific order nor a share of the total volume or corresponding revenue.

Drone System Delivered, Rollout Pending

Elsewhere, CSG has already reported delivery of its CIS+ drone system to the Czech air traffic control authority. Built on UpVision's MAIA platform, the system is designed to support drone operations within the European U-space framework. Operational implementation and certification are still to come, with full deployment expected in the second half of 2027.

CSG at a turning point? This analysis reveals what investors need to know now.

CSG also addressed the explosion at the FMG Granada munitions plant roughly two weeks ago, stating that production facilities remained undamaged and that no long-term production impact was anticipated. Two people suffered minor hearing injuries; no fatalities or serious injuries were reported.

When the nine-month figures land on November 11, the yardstick is straightforward: growth and a stable margin argue in CSG's favour, contingent on a backlog solid enough to underpin them and a full-year outlook that holds. That is precisely what the numbers — and the commentary accompanying them — will be judged against.

Ad

CSG Stock: New Analysis - 10 November

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...